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Evaluation of Efficacy and Dose Response of
Different Paclitaxel-Coated Balloon Formulations
in a Novel Swine Model of Iliofemoral
In-Stent Restenosis
Krzysztof Milewski, MD, PHD,* Maxwell Eyram Afari, MD,* Armando Tellez, MD,*
Michael S. Aboodi, BS,* Jung-Sun Kim, MD, PHD,* Yanping Cheng, MD,*
Gerard B. Conditt, RCIS,* Jennifer C. McGregor, BS,* Geng Hua Yi, MD,*
Mark Stenoien, BS,† Dan Langanki, BS,† Christian G. Krueger, BS,‡
Greg L. Kaluza, MD, PHD,* Juan F. Granada, MD*
Orangeburg, New York; Indianola, Pennsylvania; and Madison, Wisconsin
Objectives The authors aimed to validate a novel iliofemoral in-stent restenosis (ISR) model for the
efﬁcacy evaluation of paclitaxel-coated balloons (PCB) using the familial hypercholesterolemic swine
(FHS).
Background Most of the validation work regarding PCB technologies has been performed in the
coronary territory of juvenile domestic swine. Although invaluable for safety evaluation, this model
is not suited for the evaluation of the efﬁcacy of peripheral PCB technologies.
Methods Twenty-four iliofemoral segments in 12 FHS underwent balloon injury and self-expanding
stent placement. After 21 days, the resulting ISR lesions were treated with either 1 g/mm2 dose
(n  8), or 3 g/mm2 dose (n  8) PCB (Cotavance, Bayer Pharma AG/MEDRAD, Indianola, Pennsylvania),
r with an identical uncoated control balloon (n  8).
Results At termination (28 days after treatment), the percent diameter stenosis by quantitative vas-
cular analysis in the control group was higher (31.2  13.7%) compared with the 1 g/mm2 (19.3 
4.0%, 38% reduction) and 3 g/mm2 (8.6  10.7%, 72% reduction) PCB groups. Intravascular ultra-
sound analysis showed 36% (1 g/mm2 dose, p  0.04) and 55% (3 g/mm2 dose, p  0.01) reduc-
ions in neointimal volume stenosis. In the histological analysis, the control group showed the high-
st degree of percent area stenosis (65  14.3%). The reductions in percent area stenosis was 13.2%
p  0.5) and 26% (p  0.04) in the 1 g/mm
2
and 3 g/mm2 dose groups, respectively.
Conclusions The FHS model of iliofemoral ISR demonstrated a dose-dependent effect on the inhibi-
tion of neointimal proliferation of a clinically validated PCB technology. This model represents a
positive step toward the efﬁcacy evaluation of PCB in the peripheral vascular territory. (J Am
Coll Cardiol Intv 2012;5:1081–8) © 2012 by the American College of Cardiology Foundation
From the *Skirball Center for Cardiovascular Research, Cardiovascular Research Foundation, Orangeburg, New York;
†MEDRAD Interventional, Indianola, Pennsylvania; and the ‡Department of Animal Sciences, University of Wisconsin,
Madison, Wisconsin. MEDRAD Interventional provided financial support and materials for this study. Mr. Langanski is a former
employee of Bayer Interventional. All other authors have reported that they have no relationships relevant to the contents of this
paper to disclose. The first two authors contributed equally to this work.Manuscript received January 9, 2012; revised manuscript received June 12, 2012, accepted June 21, 2012.
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1082Paclitaxel-coated balloon (PCB) technologies have been
clinically introduced as an alternative therapeutic option to
drug-eluting stents in selected clinical settings (1–5). Pre-
clinical studies have shown that following balloon inflation,
short-term transfer of paclitaxel is achieved and long-term
tissue levels are maintained over time (6–9). Regardless of
its clinical use in peripheral vessels, most of the pre-clinical
validation work involving these technologies have been
performed in the coronary territory of juvenile domestic
swine (6–8). Although this model is well suited for the
evaluation of device safety, it has inherent limitations when
it comes to the evaluation of efficacy (10,11). Specifically,
there are little data in regard to the optimal drug and coating
formulation for the treatment of peripheral vessels. In the
present study, we aimed to validate a novel iliofemoral
in-stent restenosis (ISR) model for the efficacy evaluation of
PCB using the familial hyper-
cholesterolemic swine (FHS).
Methods
Device description. All balloons
used in this study had identical
material and manufacturing charac-
teristics. In the PCB group, 2 dif-
ferent paclitaxel-iopromide concen-
trations were tested (Fig. 1). One
group included the original Cota-
vance PCB with Paccocath tech-
nology at a regular dose (3g/mm2,
Bayer Pharma AG/MEDRAD,
Indianola, Pennsylvania) currently
used in clinical practice in Europe.
The other PCB group differed by
the total paclitaxel concentration (1
g/mm2). The control group con-
sisted of identical uncoated bal-
loons. All balloons used in the study
were 6 or 7 mm  20 mm, and the self-expanding stents
implanted after initial balloon inflation were 6 or 7 mm 20 mm
(Luminexx stent, Bard Peripheral Vascular, Tempe, Arizona).
Hypercholesterolemic swine model. A total of 12 FHS
7.3  0.7 months of age) obtained from the University of
isconsin Department of Animal Sciences were used in
his study. For this study, the cholesterol levels of the
nimals at baseline varied from 301 to 652 mg/dl (mean
holesterol level: 409.3  93.4 mg/dl). The FHS carries a
iver low-density lipoprotein receptor deficiency bearing a
omozygous mutation in 1 allelic mutant gene, Lpb5, at the
polipoprotein B locus, and as a consequence, naturally
evelops hypercholesterolemia (240 mg/dl) and athero-
clerosis, even if maintained under a low-cholesterol, low-
at diet (12,13). Within 2 years, these animals develop
Abbreviations
and Acronyms
%DS  percent diameter
stenosis
EEL  external elastic
lamina
FHS  familial
hypercholesterolemic swine
IEL  internal elastic lamina
ISR  in-stent restenosis
IVUS  intravascular
ultrasound
MLD  minimal lumen
diameter
NV  neointimal volume
PCB  paclitaxel-coated
balloon(s)
RVD  reference vessel
diameteromplex coronary stenotic lesions containing fibrous caps, wecrotic cores, cholesterol clefts, granular calcium deposits,
nd neovascularization, among others (12,14). By the third
ear, plaque neovascularization and hemorrhage are com-
on, with a high potential of plaque rupture (12,14). For
his study, animals were maintained on a low-grade choles-
erol diet (0.6%) to increase the cholesterol levels and to
ccelerate the disease process. Despite maintaining a low
holesterol diet, at treatment (21 days), the mean cholesterol
evel of the animals had increased by 104% (835.3  155.9
g/dl). At terminal procedure (49 days), the cholesterol
evel was 931  173.6 mg/dl). In this study, relatively
ounger animals were used on the basis of previous studies
hat demonstrated the accelerated progression of neointimal
roliferation following vascular injury despite the absence of
ignificant atherosclerotic burden found at this age (15,16).
In-stent restenosis model development. The study was ap-
roved by the Institutional Animal Care and Use Commit-
ee of Skirball Center for Cardiovascular Research. All
nimals received standard care outlined in the study proto-
ol and in accordance with the Animal Welfare Act and the
Guide for Care and Use of Laboratory Animals” formu-
ated by the Institute of Laboratory Animal Resources
National Research Council, NIH Publication No. 85-23,
evised 1996). A total of 12 castrated male juvenile FHS
ith a mean weight of 43.5  2.0 kg were included in this
tudy. A week before the initial arterial injury of the
liofemoral territory, all animals were started on a low-grade,
.6% cholesterol diet supplementation. Dual antiplatelet
herapy consisting of clopidogrel (150-mg loading dose and
5-mg maintenance dose) and oral aspirin (325-mg loading
ose and 150-mg maintenance dose) was initiated 1 day
efore the arterial injury procedure and maintained for the
ntire duration of the study. Seven days following diet
upplementation (Day 0), general anesthesia was induced
ith xylazine and Telazol (tiletamine/zolazepam). After
eaching an adequate anesthetic level, the animals were
ntubated and maintained with inhaled 1% to 3% isoflurane.
urgical access was obtained via the carotid artery with
eneral sterile technique. Before catheterization, heparin
5,000 to 10,000 U) was injected to maintain an activated
lotting time 250 s. Nitroglycerin was administered intra-
rterially to prevent and relieve vasospasm. Intravascular
ltrasound (IVUS) (iLab IVUS system; Boston Scientific,
atick, Massachusetts) was used for vessel sizing. Over-
ized balloon inflation using 1.3:1.0 balloon-to-artery
atio was applied to the target area followed by self-
xpanding bare-metal stent implantation. After 21 days,
ontrol angiography and IVUS imaging of previously
njured arterial segments were performed and then the
CB or control balloons were allocated to the target
essels per the treatment matrix. The balloons were
nflated within the stented segment for a total of 60  2 s
ith a target of 120% overstretch. Four weeks later
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1083(Day 49), terminal angiography and IVUS imaging of all
treated sites were done.
Angiographic analysis. Quantitative vascular analysis was
done at all time points using CAAS software (Pie Medical
Imaging, Maastricht, the Netherlands). The following pa-
rameters were measured using the guiding catheter as a
standard for calibration: minimal lumen diameter (MLD)
within the treated segments, and reference vessel diameters
(RVD) taken from the proximal and distal portions of the
treated sites. The balloon and stent-to-artery ratios were
calculated. Percent diameter stenosis (%DS) at pre-
procedure (Day 21) and follow-up (Day 49) were calculated
as: (1  [MLD/RVD])  100%, and the late loss was
calculated as MLD at follow up  MLD at post inflation.
IVUS analysis. IVUS pullback images were obtained and
nalyzed using a peripheral ultrasound catheter (Atlantis SR
ro 40 MHZ Imaging Catheter, Boston Scientific) and a
ommercially available measurement analytical system
iLab, Boston Scientific). Using fluoroscopy, the IVUS
atheter was placed distal to the site at which the devices
ere deployed, and the automated pullback was performed
t a speed of 1 mm/s, covering 10 mm proximal and distal
o the implantation site. The starting position of the IVUS
atheter was determined by fluoroscopy and located by
natomical landmarks in live image during the pullback.
choPlaque software version 3.0.48 (Indec Medical Sys-
ems, Santa Clara, California) was used for the analysis of
he acquired imaging pullbacks. Cross-section measure-
ents of the lumen area, stent area, and vessel area were
pplied to every 1 mm of the total 20-mm-long treated site
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Figure 1. Study Design
Figure depicting the study design ﬂow. BMS  bare-metal stent(s).o generate the following volumetric parameters: lumenolume, stent volume, vessel volume, neointimal volume
NV), and percent volume stenosis.
Histological analysis. The histological analysis was con-
ducted by an independent pathology laboratory (Alizee
Pathology, Thurmont, Maryland). After obtaining terminal
imaging, the animals were given a bolus of 10,000 U of
heparin, unless the activated clotting time within the pre-
ceding 15 min was 1,000. The animals were then eutha-
ized under anesthesia by intravenous injection of a com-
ercially available euthanasia solution, Euthasol (Virbach
H, Inc. Fort Worth, Texas) 0.2 ml/kg. Subsequently, the
reated vessels were harvested and then immersed in normal
uffered formalin 10%. For light microscopy, all treated
essels were embedded in methylmethacrylate and then 40-
o 50- m sections from the proximal, mid, and distal
portions of each stented segment were obtained. These
sections were stained with hematoxylin and eosin, and
elastic trichrome. The cross-sectional areas (external elastic
lamina [EEL], internal elastic lamina [IEL], and lumen
area) of each section were measured. These measurements
were used to calculate vessel layer areas with the following
formulas: medial EEL IEL; neointima IEL lumen;
percent area stenosis  [1  (lumen area/IEL area)]  100.
The degree of vascular injury was evaluated according to
a commonly used injury score (0 score: IEL intact, to 3
score: EEL lacerated with disruption of the media). Peris-
trut inflammation was scored according to the number of
cells around the struts (0 score: 25% struts with 10 or
fewer inflammatory cells, to 4 score: 2 or more struts
associated with granulomatous inflammatory reactions. Ad-
rolemic Swine
reation
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1084in adventitia) to 3 (moderate peripheral inflammatory infil-
tration or focally marked in 50% of adventitial area).
Fibrin deposits were scored from 0 (none to focal residual
fibrin involving any portion of the artery) to 3 (heavy
deposition of fibrin involving 25% of the circumference of
artery or surrounding50% of stent struts). Endothelial cell
coverage was scored according to the percentage of lumen
circumference covered by the endothelium (0: 25%, 1:
25% to 75%, 2: 75% to 95%, and 3: 95%).
Statistical analysis. Statistical analysis was conducted using
he statistical software SigmaPlot v. 11.0 (Build 11.2.0.5,
YSTAT Software, San Jose, California). Summary statis-
ics; means and standard deviations were calculated using
icrosoft Excel spreadsheets (Excel 2007, v12, Microsoft,
edmond, Washington). All continuous data were ana-
yzed by conducting an analysis of variance (ANOVA) to
etermine significant difference (p  0.05) between
roups. If a difference was detected by ANOVA, and the
ata were considered normally distributed and variances
ere homogeneous, a Holm-Sidak test was run to com-
are test subjects and the control. Otherwise, the data
ere analyzed by Kruskal-Wallis ANOVA and Dunn’s
est. For the semiquantitative (ordinal) histological data,
he Kruskal-Wallis test (with Dunn’s method) was per-
ormed. A value of p  0.05 was considered statistically
ignificant.
esults
Angiographic analysis. Before injury, the average angio-
graphic vessel diameters were comparable among all groups
(control: 4.42 0.54 mm, 1 g/mm2: 4.77 0.53 mm, and
3 g/mm2: 4.59  0.92 mm, p  0.76). Angiographic
nalysis demonstrated that the degree of injury achieved in
ll groups was comparable (balloon-to-artery ratio  con-
rol: 1.25  0.1, 1 g/mm2: 1.24  0.09, and 3 g/mm2:
.34  0.15, p  0.11). Also, the final stent-to-artery ratio
as similar among all the groups (control: 1.11  0.14, 1
g/mm2: 1.11  0.1, and 3 g/mm2: 1.19  0.15). A
summary of angiographic data is presented in Table 1.
At the time of PCB treatment (21 days), all the baseline
angiographic variables were comparable among all groups.
The mean baseline %DS was similar among all treated
groups (Table 1). In addition, the mean final balloon
inflation diameters were also comparable (control: 4.8 0.6
mm, 1 g/mm2: 4.7  0.7 mm, and 3 g/mm2: 5.0  0.8
mm, p  0.77) when measured at their maximal inflation
oint, leading to a similar angiographic MLD immediately
ost vessel treatment (control: 3.5  1.0 mm, 1 g/mm2:
.5  1.0 mm, and 3 g/mm2: 3.7  0.8 mm, p  0.86).
Terminal angiographic evaluation demonstrated a lower
%DS in the 3 g/mm2 treatment group (p  0.03) and the
g/mm2(p  0.2) compared with the control uncoatedballoon. The 3 g/mm2 dose balloon reduced stenosis by72% compared with the control group, whereas the
1 g/mm2 dose reduced restenosis by 38%. In addition, the
final MLD was significantly higher in the 3 g/mm2
(4.08  0.8 mm) and 1 g/mm2(3.69  0.73 mm) groups
compared with the control balloon (2.8  0.5 mm, p 
0.01). As a result, there was a significant reduction in
angiographic late loss in both PCB groups compared with
the uncoated balloon group (Table 1).
IVUS analysis. A summary of IVUS data is presented in
able 2. IVUS analysis revealed that the percentage volume
tenosis at the time of PCB treatment (Day 21) was
omparable among the groups (control: 37.6  25.3%, 1
g/mm2: 38.8 26.1%, and 3 g/mm2: 28.9 15.7%, p
0.52). At termination (49 days), both PCB groups showed
significantly lower NV and percent volume stenosis as
compared with the control group (p  0.001 for both
parameters). In addition, the lumen volume at termination
was significantly higher in both PCB groups compared with
the control balloon group (Table 2, Fig 2). In the 3 g/mm2
dose group, both NV and % volume stenosis were reduced
by 56% (p  0.001) compared with the control group. The
1 g/mm2 group showed 34.3% (p  0.1) and 35.7% (p 
0.04) reductions in NV (Fig. 2B) and % volume stenosis,
respectively. After adjustment for the degree of NV found at
termination in comparison with the pre-treatment values
(Day 21), compared with the control group (163.8 mm3 
90), the least change in neointimal proliferation was found
in the 3 g/mm2 treatment group (2.4  74 mm3, p 
.008), followed by the 1 g/mm2 group (31.1 mm3  97
mm2, p  0.02). IVUS analysis demonstrated that the
pattern of neointimal inhibition was homogeneous through-
Table 1. Angiographic Data at Baseline, Time of Balloon Treatment, and
Last Follow-Up
Control Group
Uncoated
1 g/mm2
Dose
3 g/mm2
Dose
p
Values
Day 0 (baseline) n  8 n  8 n  8
RVD, mm 4.4 0.5 4.8 0.5 4.6 0.9 0.76
BAR 1.3 0.1 1.24 0.01 1.3 0.2 0.11
SAR 1.1 0.1 1.1 0.1 1.2 0.12 0.06
Day 21 (procedure) n  8 n  8 n  8
MLD, mm 3.1 1.1 3.1 1.1 3.7 0.8 0.53
%DS 31.1 23.7 34.7 21.9 20.5 12.7 0.46
Balloon diameter, mm 4.8 0.6 4.7 0.7 5.0 0.8 0.77
Post-treatment MLD, mm 3.5 1.0 3.5 1.0 3.7 0.8 0.86
Day 49 (follow-up) n  8 n  8 n  8
MLD, mm 2.8 0.48 3.7 0.7* 4.1 0.8* 0.01
%DS 31.2 13.7 19.3 14.1 8.6 11* 0.01
LL, mm 0.6 0.9 0.2 0.58 0.5 0.8 0.09
Values are mean SD. *p 0.05 versus uncoated.
%DS percent diameter stenosis; BAR balloon to artery ratio; LL late loss; MLDminimal
lumen diameter; RVD reference vessel diameter; SAR stent-to-artery ratio.out the length of the stent in both PCB groups (Fig. 3).
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1085Histological evaluation. A summary of histological data is
resented in Table 3. The histomorphometric analysis
howed a constant IEL area (stent area) between all treat-
ent groups (control; 26.3  4.9 mm2, 1 g/mm2: 27.3 
.0 mm2, and 3 g/mm2: 27.9 5.7 mm2). Compared with
he uncoated control, the 3 g/mm2 dose increased the
lumen area by 65% (p 0.04) and decreased the percentage
area stenosis by 26% (p  0.04). Meanwhile, in the 1
g/mm2 dose group, although there was a trend towards
efficacy, the difference did not reach statistical significance
(lumen area control: 8.9 3.4 mm vs. 1 g/mm2: 11.7 3.4
mm, p 0.7) and percent area stenosis (control: 65.0 14.3%
vs. 1 g/mm2: 56.4  14.3%, p  0.7). The neointimal
thickness of the control (1.3  0.5 mm) was slightly higher
than that of 1 g/mm2 dose (1.01  0.4 mm, p  0.5) but
onsiderably higher than the 3 g/mm2 dose (0.8  0.2
m, p  0.08). No significant effect of treatment on EEL
nd medial area was observed (Table 3). The vessel wall
njury was proportional between the control group (0.5 
.5) and both test groups (1 g/mm2: 0.4  0.5, and 3
g/mm2: 0.3  0.2). There was a higher degree of fibrin
deposits in the PCB (1 g/mm2 dose: 0.7  0.5, and 3
g/mm2 dose: 0.6  0.4) as compared with the control
roup (0.2  0.2). The struts were almost completely
overed with endothelium at 28 days follow-up in all
tudied groups as shown in Table 3. The average peristrut
nflammation score was lower in the control group (0.5 
.9, p  0.83) compared with the 1 g/mm2 dose (0.9 
.0) and 3 g/mm2 dose (0.5  0.6) groups. The mean
adventitial inflammation in the control group (0.6  0.6,
p  0.95) was also comparable to that of the 1 and 3
Table 2. Summary of IVUS Data at Time of Treatment and Last Follow-Up
Control Group
Uncoated
1 g/mm2
Dose
3 g/mm2
Dose
p
Values
Day 21 n  7 n  8 n  8
LV, mm3 346.6 166 334.2 176 386.8 127 0.89
SV, mm3 547.6 80 534 103 539.1 113 1
VV, mm3 677.4 118 667.2 116 680.7 162 0.98
NV, mm3 201 135 199.8 132 152.2 85 0.43
%VS 37.6 25.3 38.8 26.1 28.9 15.7 0.52
Day 49 n  8 n  8 n  8
LV, mm3 242.5 71 383.2 124* 485.8 161* 0.02
SV, mm3 594.3 125 614 130 640.4 140 0.97
VV, mm3 784.7 180 807.7 172 831.2 185 0.98
NV, mm3 351.7 131 230.9 115 154.7 33* 0.001
∆NV 163.8 90 31.1 97 2.4 74 —
%VS 58.3 11.6 37.4 17.0* 25.5 8.6* 0.001
Values are mean SD. The neointimal volume increase is presented as a difference between NV
at Day 21 and NV at Day 49. *p 0.05 versus uncoated.
%VS percent volume stenosis; IVUS intravascular ultrasound; LV lumen volume; NV
neointimal volume; SV stent volume; VV vessel volume;NV neointimal volume increase.g/mm2 doses (0.6  0.4 and 0.7  0.6), respectively.Discussion
Although PCB technologies have been already tested in
different experimental and human clinical trials (1–5,7),
there are still little data in regard to the optimal dose and
coating formulation for peripheral vascular applications. It
has been proposed that the biological efficacy of PCB
depends on the optimal development of a drug formulation
and specific coating methods (17). Similarly, there are not
enough published data to suggest that similar drug coating
formulations previously validated in the swine coronary
territory would be equally effective in peripheral vascular
applications. The peripheral vascular territory is biologically
different, and it is known to be subject to different mechan-
ical forces and to react differently from endovascular thera-
pies compared with other vascular beds (18).
Predicting clinical efficacy in nondiseased animal models has
proven to be challenging (10,11). The biological nature and
progression of neointimal formation in a normal swine artery
greatly deviates from what is observed in human atherosclerotic
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Figure 2. Lumen Volume and Neointimal Volume at Last
Follow-Up by IVUS
There is a clear dose-response effect (1 g/mm2 vs. 3 g/mm2) of both
PCB technologies in comparison with the uncoated control group. (A)
Lumen volume; (B) neointimal volume. *p  0.05. IVUS  intravascular
ultrasound; NV  neointimal volume.
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1086lesions. Thus, in this study, we chose to use a diseased and
clinically relevant model of ISR in the peripheral territory of
the FHS. This model provides a metabolic profile and a
vascular territory similar in diameter and anatomic config-
uration to the human peripheral arteries. However, due to
the short duration of the study, low-grade cholesterol diet
supplementation and vascular injury were added to acceler-
ate the disease process. The use of balloon and stent
overstretch has been previously described by Schwartz et al.
(19) and subsequently has been extensively used for the
validation of safety of stents in the swine. Previous data
published by our laboratory have shown that the FHS
model displays a different pattern of neointimal proliferation
and healing following bare-metal stent coronary implanta-
tion compared with the domestic swine model (15,16). The
utility of this model has been demonstrated in the evalua-
tion of efficacy of drug-eluting stents (20) and peripheral
drug-coated balloons (16). We then hypothesized that the
combination of the intrinsic metabolic defect of the FHS
and vessel wall injury would be sufficient to demonstrate
efficacy differences following the use of different PCB
treatment dosages when compared with an uncoated control
balloon (Fig. 4).
The results of this study demonstrated a dose-dependent
response on neointimal inhibition of the 2 tested PCB
dosages as compared with the uncoated control balloons.
This response was consistent and statistically different across
all analytical methods used in this study. Both quantitative
vascular analysis and IVUS analysis demonstrated a dose-
dependent effect on inhibition of neointimal formation
when compared with the uncoated control group. A con-
siderably lower angiographic late loss was achieved in both
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Figure 3. Pattern of In-Stent Neointimal Distribution Along the Treated Seg
The homogeneous distribution pattern suggests a uniform biological effect fopaclitaxel-treated groups (1 g/mm2: 0.2  0.56 mm, a3 g/mm2 dose: 0.5  0.8 mm) compared with the
uncoated balloon group (0.6  0.9 mm). However, the 1
g/mm2 dose PCB did not seem to be as effective as the
3 g/mm2 dose in inhibiting neointima. Although the 1
g/mm2 dose consistently reduced neointimal formation in
comparison with the control uncoated balloon, it remained
statistically inferior when compared with the 3 g/mm2
dose PCB. The angiographic findings seen using the 3
g/mm2 dose appears to be consistent with the findings
een in human trials using the same Cotavance Paccocath
echnology, whereby after 6 months, this dose reduced
ngiographic late loss by 50% (0.5  1.1 mm) and 76%
0.4  1.2 mm) in the FemPac (Femoral Paclitaxel) and
HUNDER (Local Taxane with Short time Exposure for
eduction of Restenosis in Distal Arteries) trials, respec-
ively (1,4).
At 49 days, the injury scores were similarly low in both
ested groups, indicating homogeneity of the method used
nd the similar biocompatibility of the tested technology.
he injury scores in the PCB group tended to be the response
o both mechanical injury and drug effect. The degree of
iocompatibility seemed to be confirmed by the low inflam-
ation scores whose means were almost identical (1.0
25% with 10 inflammatory cells] in all tested groups).
lthough no statistical difference was found among the
roups, there was a trend towards greater fibrin deposits in
oth PCB groups as compared with the uncoated control
roup. The fibrin presence in the tissue is a typical finding
or technologies that use antiproliferative agents, reflecting
he biological effects of drug transfer to the vessel wall
21–24). The presence of fibrin at long term has been
onsidered a marker of delayed healing, and it has been
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initial delivery. IVUS  intravascular ultrasound.1
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1087present study, fibrin scores were consistently low, with a
maximal level of 0.7 (where 1.0 represents mild fibrin
deposition involving 10% of the circumference of the
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Figure 4. Representative Images at 49 Days Follow-Up in Angiography, IVU
Representative images at 49 days follow-up in angiography (A, B, and C), intr
uncoated balloon group showed the highest degree of neointimal proliferatio
formation was observed in both the 1 g/mm2 (B, E, and H) and 3 g/mm2 (
Table 3. Histomorphometry and Qualitative Histological Analysis at
Last Follow-Up
Control Group
Uncoated
1 g/mm2
Dose
3 g/mm2
Dose
p
Value
Lumen area, mm2 8.9 3.4 11.7 3.4 14.6 4.3* 0.04*
IEL area, mm2 26.3 4.9 27.3 4.0 27.9 5.7 0.98
EEL area, mm2 29.3 5.2 30.4 4.6 31.4 6.6 0.96
Medial area, mm2 3.0 0.4 3.1 1.0 3.5 1.3 0.77
Neointimal area, mm2 17.4 7 15.6 5.2 13.3 3.2 0.37
% area stenosis 65.0 14.3 56.4 14.3 47.9 8.8* 0.04*
Peristrut inﬂammation 0.5 0.9 0.9 1.0 0.5 0.6 0.83
Adventitial inﬂammation 0.6 0.6 0.6 0.4 0.7 0.6 0.95
Endothelial coverage 3.0 0.1 2.9 0.2 2.8 0.4 0.42
Fibrin deposition 0.2 0.2 0.7 0.5 0.6 0.4 0.13
Vessel wall injury 0.5 0.5 0.4 0.5 0.3 0.2 0.96
Values aremean SD. Percent area stenosiswas determinedby: (1 lumen area/IEL area) 100.
*p 0.05 versus uncoated.
EEL external elastic lamina; IEL internal elastic lamina.degree of neointima inhibition. LIF  left iliofemoral artery; QVA  quantitative vascartery, or around 25% of stent struts). In addition, no
negative effects of the drug formulation were found with
regard to other histological parameters such as inflamma-
tion, IEL, EEL, and smooth muscle cell loss.
Study limitations. Several limitations were present in the
urrent study. First, there are clear differences in the
natomical and biological composition between human
therosclerotic lesions and relatively normal arteries seen in
he FHS. In addition, there are no established parameters to
ompare the efficacy results found in this study to clinical
rial results, hence making it difficult to extrapolate these
esults to humans. However, it is important to highlight
hat the 3 g/mm2 dose PCB group, efficacious in this
tudy, is the drug formulation successfully used in humans
nd presently used in clinical practice. Also, although
ong-term positive clinical data have been already presented
sing this technology, the long-term vascular effects of the
se of this technology, especially in the setting of the
hronic presence of self-expanding stents, have not yet been
ested in this model. At the present time, the domestic
wine remains the standard experimental model for the
3-µg/mm² PCB² PCB C
I
F
d Histology
lar ultrasound (IVUS) (D, E, and F), and histology (G, H, and I). The
, and G) within stents (pointed arrows). An evident decrease in neointimal
and I) paclitaxel-coated balloon (PCB) groups, the latter showing the highestse, 
g/mm
S, an
avascu
n (A, D
C, F,ular angiography; RIF  right iliofemoral artery.
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1088evaluation of device safety. This model is cost effective and
well characterized for the validation of safety of coronary
devices. However, the utility of the domestic swine model
for the evaluation of device efficacy is very limited. There-
fore, the FHS-ISR peripheral model may provide additional
value in the validation of efficacy (i.e., dose response) of
peripheral vascular technologies.
Conclusions
In summary, a novel iliofemoral model of ISR based on the
FHS demonstrated the biological efficacy of several PCB
formulations in a dose-dependent fashion. The efficacy
effect seems to be comparable to what has been presented in
human clinical trials of superficial femoral artery interven-
tion using this technology (1,4). The efficacy response
observed in this study suggests that this model may repre-
sent a step forward towards the evaluation of efficacy of
peripheral vascular technologies.
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